May 15, 2024

A new study published today in the Journal of Clinical Oncology provides compelling evidence that genital talc use is associated with an increased risk of ovarian cancer. This extensive analysis, part of the Sister Study cohort, revisits the association between intimate care products and cancer, incorporating rigorous adjustments for biases that might have affected earlier studies. 

May 15, 2024

A new study published in the Journal of Clinical Oncology shows encouraging results for the combination therapy of pertuzumab and trastuzumab in treating advanced biliary tract cancer (BTC) with ERBB2/3 alterations. The incidence and mortality rates of BTC have risen significantly in recent years, with a 5-year survival rate of only 2% for patients with metastatic disease. 

May 6, 2024

The American Society of Clinical Oncology (ASCO) announced four additional medical schools have been selected to participate in the Society’s Oncology Summer Internship (OSI) Program.

April 29, 2024

Patients with KRASG12C mutated-non-small cell lung cancer (NSCLC) who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings that will be presented in the upcoming April 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

April 25, 2024

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are calling on manufacturers of diagnostics and therapeutics to adopt therapeutic group labeling to improve access to effective modern therapies for patients,

April 24, 2024

The global oncology community will gather in Chicago to share and discuss the latest clinical cancer research impacting patient care at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Treatment advances involving targeted therapies, immunotherapy, and new uses of technology, as well as research on improving patient quality of life and outcomes are among the topics that will be highlighted in the meeting’s official Press Program.  

April 17, 2024

Cancer doctors from across the U.S. are lending their voices to a new advocacy campaign to end drug shortages. Led by the Association for Clinical Oncology (ASCO), nearly 500 oncology professionals have signed an open letter to Congress and the administration highlighting the severe impact of drug shortages on cancer care and urging swift action from lawmakers.

March 28, 2024

Today the Department of Health and Human Services (HHS), Department of Labor and the Treasury Department finalized a rule regulating the availability of short-term limited duration insurance (STLDI) plans. The rule would restrict the availability of these plans to no more than four months.

March 22, 2024

Congress is expected to vote on a spending package March 22 that will fund the federal government, including the National Institutes of Health (NIH) and National Cancer Institute (NCI), through September 30— the end of the 2024 Fiscal Year.

March 14, 2024

A new ASCO policy statement is emphasizing the urgent need for global equity in clinical trials. The statement, which published March 14, 2024, in JCO Global Oncology, explains how global equity can be advanced by diversifying trial representation, increasing access to resources, and strengthening research capacity on a global scale.

March 7, 2024

The Association for Clinical Oncology (ASCO) is calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. 

February 28, 2024

The President's Cancer Panel issued a report on Feb. 28 on the National Cancer Plan that highlights seven ASCO programs that are contributing to the plan.

February 22, 2024

The American Society of Clinical Oncology (ASCO) released a policy statement highlighting the top policy changes necessary to advance health equity in cancer care. The statement, published in JCO Oncology Practice, examines how social determinants of health (SDOH) can impact a patient’s access to cancer care and outcomes.

February 6, 2024

Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer & Executive Vice President of the Association for Clinical Oncology (ASCO), will testify before the full House Committee on Ways and Means on the crisis of ongoing cancer drug shortages. Dr. Gralow will share ASCO members’ firsthand experiences managing clinical care in the face of severe shortages. She will also urge Congress to take action to help mitigate the problem.

February 5, 2024

In a head-to-head study, the triplet therapy of belantamab mafodotin (belamaf) plus bortezomib, and dexamethasone (BVd) demonstrated a significantly improved progression-free survival compared to the current standard of care in patients with relapsed or refractory multiple myeloma. These results will be presented during the February 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.